中文簡介
企業概述
江蘇歐威醫藥有限公司成立於2012年8月6日，是江蘇先聲藥業控股的創新藥物研發企業，是江蘇先聲藥業"百家匯"項目的第一家註冊公司，註冊資金500萬元人民幣。 2012年歐威公司申報南京"321"人才計畫，獲得200萬元重點扶持。主要產品
至2013年，公司現有在研創新項目3個，腦卒中藥物項目已進入臨床二期研究，另兩個項目進入臨床前研究階段。歐威醫藥研發團隊專業領域全面，主持或參與過先聲藥業多個一類新藥的研發申報過程。展望未來
歐威醫藥將依託先聲藥業的強大研發平台和資金投入，引進國外先進項目或推動內部項目走向國際，努力打造有世界影響力的藥物。英文簡介
Founded on August 6th, 2012, Jiangsu Simovay Pharmaceutical Co., Ltd (Simovay) is a fully owned subsidiary of JiangSu Simcere Pharmaceutical Co., Ltd (Simcere). It’s also the first entity supported by “100 R & D Companies” project, with the registration capital of ￥5 million. In 2012, Simovay has applied Nanjing “321” talent projects, and was successfully awarded with ￥2 million research support. So far, Simovay has 3 innovative pipeline projects. Among them, an ischemic stroke project is undergoing phase II clinical trial, and the other two are at pre-clinical stage.Simovay is a professional and energetic team, with broad and strong scientific backgrounds. The management team has led/participated in the development and filing process of more than one novel therapeutic drug in Simcere. With the support of established discovery platforms and capital investment from Simcere, Simovay will be devoted to in-licensing potential drug candidates from abroad, as well as advancing in-house drug development, so as to build Simovay a world-leading pharmaceutical company.
